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The restriction enzyme Eco RI identifies a two-allele system for
the L-myc gene with fragment sizes of 10.0 and 6.6 kilobases and
results in three possible allelotypes: homozygotic for the large
allele (LL), homozygotic for the small allele (SS) or heterozygotic
(LS). The prognostic significance of the L-myc allelotype of
genomic DNA has been studied previously in several tumours
(lung, colorectal, breast, soft tissue, leukaemia, lymphoma,
stomach, kidney, oral cavity and liver). However, conficting
results were reported. In this study we have investigated the L-myc
genotype of 98 primary bladder cancer patients in an attempt to
determine its utility as a prognostic, and as a susceptibility, factor
in a Catalonian population.
MATERIALS AND METHODS
Ninety-eight patients (88 males, 10 females, aged 38–91), diag-
nosed at Fundació Puigvert as having primary bladder cancer, were
studied for L-myc restriction fragment length polymorphism
(RFL); P 53 were superficial bladder tumours and 45 were invasive
tumours. In addition, 110 normal DNA specimens from healthy
blood donors (66 males, 44 females, aged 2–81) were analysed to
investigate the genotype frequency of L-myc proto-oncogene.
High molecular weight DNA was isolated by standard
phenol–chloroform methods. Restriction digests of DNA were
performed with endonuclease Eco RI under standard conditions,
electrophoresed in a 0.8% agarose gel, denaturated, transferred to
Hybond® nylon membrane (Amersham) and hybridized with a
32P-labelled probe by the method essentially described by
Southern (1975).
All results obtained in these studies were analysed for statistical
significance by the c2 test with Yates’ correction for adjustment
when necessary. Differences between the two populations were
judged significant at P < 0.05. Kaplan–Meier curves were
constructed to analyse patient survival between different geno-
types (log-rank test).
RESULTS
Eco RI-digested DNA probed with the L-myc probe results in two
fragments of 10 kb (L) and 6.6 kb (S), which are due to an Eco RI
restriction site polymorphism (Figure 1). The distribution of the
three genotypes (LL, LS, SS) in the control and patient groups is
shown in Table 1. Chi-squared analysis showed that there was
no difference between the distribution of the three genotypes
of patient group and controls, and all are in accordance with
Hardy–Weinberg equilibrium.
When the patients in the current study were examined for a rela-
tionship between the presence of S-alleles (LS or SS individuals)
and distant metastasis, no association was found (P = 0.51). Nor
was there a significant association between homozygosity for the
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Figure 1 Examples of Southern hybridization analysis of the L-myc gene.
DNA samples obtained from peripheral leucocytes of five control individuals
are shown. Genotypes of lanes 1 and 3 were LL, that of lane 2 was LS, and
those of lanes 4 and 5 were SSS-allele and nodal metastasis (P = 0.46). Further analysis revealed
no significant associations with grade of differentiation of
tumours, TNM stages, number of previous and subsequent
relapses, and urethral and prostate involvement (Table 2). No
association was observed between L-myc RFLP and survival of
bladder cancer patients (Figure 2).
DISCUSSION
An Eco RI polymorphism of the L-myc proto-oncogene was
reported with the initial description of the gene (Nau et al, 1985)
and the site of the polymorphism subsequently located in the
second intron (Kaye et al, 1988). Studies of this polymorphism
have linked it to both cancer susceptibility and prognosis. The role
of L-myc in cancer susceptibility has been implied by studies
showing differences in genotype frequencies between cancer
patients and controls (Kato et al, 1990; Dolcetti et al, 1991; Crossen
et al, 1994). The role of L-myc in prognosis has been suggested by
studies showing that, among cancer patients, those that carry an S-
allele (either LS or SS genotype) have earlier lymph node involve-
ment or metastasis, or poorer survival than those who have
genotype LL (Kakehi and Yoshida, 1989; Champeme et al, 1992;
Kawashima et al, 1992). In contrast, Taylor et al (1993) reported a
protective effect for the SS genotype in hepatocellular carcinoma.
Hence, the association of the L-myc genotype with susceptibility
and prognosis appears to vary with tumour type.
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Table 1 Distribution of L-myc genotypes and allele frequencies in patients and normal controls
Genotypes Allele frequency
LL LS SS Total c2 (P)L S( P)
Controls 40 45 25 110 0.568 0.432
Patients 32 45 21 98 0.546 > 0.05 0.556 0.444 > 0.05
Table 2 Data on patients with bladder cancer and the distribution of the L-myc genotypes
DNA pattern of L-myc no. of cases
Total number Total LL LS SS
Age (years)
< 60 10 3 6 1
61–70 37 16 16 5
> 70 51 14 26 11
Sex
Male 88 28 44 16
Female 10 4 1 5
Smoking
Yes 71 23 34 14
No 27 9 11 7
Grade of differentiation
G1 + G2 45 14 19 12
G3 + anaplas. + indifferentiated 53 18 26 9
TNM stages
Ta + T1 53 18 25 10
T2 + T3 + T4 45 14 20 11
Recurrencea
R + 46 11 26 9
R – 52 21 19 12
Distant metastasisb
M + 28 7 15 6
M – 68 25 29 14
Nodal metastasisc
N + 15 4 9 2
N – 71 26 30 15
Urethral involvement
U + 5 – 3 2
U – 93 32 42 19
Prostate involvementd
P + 9 2 5 2
P – 79 26 39 14
aNumber of patients with previous relapses (R+) versus number of patients without previous relapses (R–). bThis variable was not
possible to examine in two cases. cThis variable was not possible to examine in 12 cases. dTen female patients were excluded of this
examination.In this study, we examined the relationship between the L-myc
RFLP pattern and the clinical features of bladder cancer in 98
cases. A preponderance of the LL, LS or SS fragments was not
observed in the bladder cancer patients compared to normal
healthy individuals; thus, presence of a particular allele did not
indicate predisposition to bladder cancer. Similar L-myc allelic
frequencies were also found in previously reported analyses.
Our results fail to support the hypothesis that the L-myc locus is
involved in a genetic predisposition to bladder cancer. These
results confirm those of Ikeda et al in colorectal cancer (1988),
Tefre et al in lung cancer in Norway (1990), Ishizaki et al (1990)
and Champeme et al (1992) in breast cancer, Saranath et al (1990)
in oral cancer, Weston et al (1992) in lung cancer in the USA,
Mironov et al (1994) in gastric cancer in Russia and Presti et al
(1996) in renal cancer. On the other hand L-myc RFLP is corre-
lated with the extent of metastasis of lung cancer in Japan
(Kawashima et al, 1988, 1992) and in renal cancer (Kakehi and
Yoshida, 1989); Ishizaki et al (1990) also reported that the pres-
ence of the S-allele is associated with poor prognosis due to
metastasic lesion in gastric cancer. Kato et al (1990) proposed that
Japanese men with the S-allele may be prone to development of
osteosarcoma and Saranath et al (1990) observed that patients with
oral cancer with a genotype including an S fragment are more
likely to develop a poorly to moderately differentiated tumour, or a
larger tumour, than patients without an S fragment.
Our results show that the L-myc genotype does not correlate
with tumour grade or stage in patients with bladder carcinoma. No
significant correlation was observed between the L-myc genotype
and the presence of nodal metastases or distant metastases at the
time of surgery or with subsequent disease relapse.
This study did not demonstrate an association between the
L-myc genotype and disease status in bladder cancer. It seems
that L-myc polymorphism is not suitable as a prognostic and
susceptibility marker in the bladder cancer patients studied.
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